The Smarter Drug Approval Path Most Companies Still Ignore: A Comparative Analysis of 505(b)(2) and 505(b)(1) Regulatory Pathways
In the fiercely competitive world of pharmaceutical innovation, time is more than money — it’s a matter of life and death. Yet, many companies are still navigating the complex maze of drug approval pathways with outdated strategies, risking delays, inc…
